Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
- Written by PR Newswire
![]() |
- COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease
- SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
- SKB378/WIN378 has the potential to be the first-to-market,ultra long-acting anti-TSLP antibody for asthma and...















